NCT04498780Completed
Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure
Hemodynamic Effects of Angiotensin Receptor Neprilysin Inhibition on Noninvasive Pressure-volume Analysis in Patients With Heart Failure With Reduced Ejection Fraction
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
Sacubitril-Valsartan reduced heart failure hospitalizations and cardiovascular mortality compared to enelapril in chronic heart failure. Furthermore, quality of life is improved. The decrease of NT-proBNP levels during Sacubitril-Valsartan treatment is associated with reverse left ventricular remodeling and improved left ventricular systolic function. However, the underlying mechanisms that contribute to these symptomatic and prognostic benefits are largely unknown. The aim of this study is to evaluate left ventricular hemodynamics in patients treated with Sacubitril-Valsartan using non-invasive pressure-volume analysis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 117 (actual)
- First submitted
- 29 Jul 2020
- Start date
- 21 Jul 2020
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- University of Leipzig
- Diseases
- Heart failure
- NCT number
- NCT04498780
What you commit to
- Study type: Observational
- Participants enrolled: 117
- From 21 Jul 2020 to the primary completion date, 31 Dec 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- catecholamine therapy at inclusion
- existing therapy with Sacubitril-Valsartan
Other illness
- planned cardiac resynchronization therapy (CRT) within 6 months; inclusion at least 3 months after CRT
- participation in another randomized heart failure trial
Other
- planned mitral or aortic valve procedure within 6 months; inclusion at least 3 months after valve procedure
- severe aortic or mitral valve lesion
Who the study is looking for
- Symptomatic heart failure (NYHA functional class II to IV)
- Reduced LV ejection fraction (≤ 40%)
- Clinical indication for therapy with Sacubitril-Valsartan
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Kardiopraxis Schirmer Coordinator of this site? Confirm its status | Kaiserslautern | Germany | Unknown status |
| University of Leipzig Coordinator of this site? Confirm its status | Leipzig | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.